Benefits in doubt: 50% of drugs fail to impress Germany
This article was originally published in Scrip
Executive Summary
According to Scrip's research, many companies are evidently having a difficult time demonstrating to German health technology authorities that their products offer sizeable additional benefits. The table below shows which medicines have come out on top, and which have struggled.